Table III.5

Table III.5: Reported Provisions Related to Labeling and Testing of Compounded Drug Products, by Reporting State, as of January 1, 2016
State	Compounded drug products are required to have labeling that indicates that the drug is a compounded drug	Nonsterile compounded drugs are subject to random or routine sampling for potency and purity	Sterile compounded drugs are subject to random or routine sampling for potency, purity, and sterility
Alabama	No	No	No
Arizona	-	Yes	Yes
Arkansas	Yes	No	Yes
California	Yes	Yes	Yes
Colorado	Yes	No	Yes
Connecticut	Yes	No	No
Delaware	No	No	No
District of Columbia	No	No	No
Florida	Yes	No	No
Georgia	Yes	Yes	Yes
Guam	No	No	No
Hawaii	Don't know	Don't know	Don't know
Idaho	Yes	Yes	Yes
Illinois	-	Yes	Yes
Iowa	Yes	Don't know	Don't know
Kansas	Yes	No	No
Kentucky	No	No	No
Louisiana	No	No	No
Maine	-	-	-
Maryland	-	-	-
Massachusetts	Yes	No	Yes
Michigan	Don't know	Don't know	Don't know
Minnesota	No	No	No
Mississippi	No	No	No
Missouri	No	No	Yes
Montana	Yes	No	No
Nebraska	Yes	No	Yes
Nevada	Yes	Yes	Yes
New Hampshire	Yes	Yes	Yes
New Jersey	Yes	Yes	Yes
New Mexico	No	No	Yes
New York	Yes	No	No
North Carolina	No	Yes	Yes
North Dakota	No	Yes	Yes
Ohio	Yes	Yes	Yes
Oklahoma	Yes	Yes	Yes
Oregon	No	Yes	Yes
Pennsylvania	No	No	No
Rhode Island	No	No	Yes
South Carolina	No	No	No
South Dakota	No	No	No
Tennessee	Yes	Don't know	Yes
Texas	Yes	No	Yes
Utah	Yes	No	Yes
Vermont	Yes	No	No
Virginia	Yes	No	No
Washington	No	Yes	Yes
West Virginia	-	-	-
Wisconsin	No	No	No
Wyoming	Yes	No	Yes

^{Source: GAO survey of state pharmacy regulatory bodies, survey question 15. | GAO-17-363SP}

Note: GAO surveyed the state pharmacy regulatory bodies in the 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands, and all but 4 completed the survey.